login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SANOFI-ADR (SNY) Stock News
USA
- NASDAQ:SNY -
US80105N1054
-
ADR
49.63
USD
+0.74 (+1.51%)
Last: 11/21/2025, 8:00:43 PM
49.63
USD
0 (0%)
After Hours:
11/21/2025, 8:00:43 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SNY Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Zacks Investment Research
- Mentions:
REGN
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
11 days ago - By: Zacks Investment Research
- Mentions:
ACN
DVMT
DELL
The Zacks Analyst Blog Accenture, Sanofi and Dell
11 days ago - By: Zacks Investment Research
- Mentions:
ACN
DVMT
PEG
PCG
...
Top Research Reports for Accenture, Sanofi & Dell Technologies
11 days ago - By: The Motley Fool
Why Roche Holding Stock Popped Today
12 days ago - By: Investor's Business Daily
- Mentions:
TGTX
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results
13 days ago - By: Investor's Business Daily
- Mentions:
MRK
REGN
AMGN
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%
a month ago - By: Investor's Business Daily
- Mentions:
AAPL
Sanofi Jumps As Third-Quarter Dupixent Sales Near $5 Billion
a month ago - By: Benzinga
Examining the Future: Sanofi's Earnings Outlook
2 months ago - By: Stocktwits
- Mentions:
IMRX
Why Immuneering Stock Soared Over 40% After-Hours Today
2 months ago - By: Benzinga
Is Sanofi Gaining or Losing Market Support?
15 days ago - By: Zacks Investment Research
- Mentions:
NVAX
ANIP
ARQT
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
25 days ago - By: Medidata Solutions, Inc.
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
a month ago - By: Medidata Solutions, Inc.
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
a month ago - By: Zacks Investment Research
- Mentions:
AZN
MRK
Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
a month ago - By: Stocktwits
- Mentions:
RVMD
IRON
REGN
LLY
...
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program
a month ago - By: EVOQ Therapeutics, Inc.
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
a month ago - By: Zacks Investment Research
- Mentions:
TEVA
ALLO
CMMB
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
a month ago - By: Zacks Investment Research
- Mentions:
REGN
REGN Reports Encouraging Data on Gene Therapy for Genetic Hearing Loss
a month ago - By: Zacks Investment Research
- Mentions:
WMT
SNE
C
JBLU
...
Top Research Reports for Walmart, Sony & Citigroup
a month ago - By: Investor's Business Daily
- Mentions:
APGE
REGN
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
2 months ago - By: The Motley Fool
- Mentions:
NKTR
REGN
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
2 months ago - By: Zacks Investment Research
- Mentions:
TEVA
FOLD
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
2 months ago - By: Zacks Investment Research
- Mentions:
GILD
KYMR
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
2 months ago - By: Stocktwits
- Mentions:
NVAX
Novavax Amends Deal With Sanofi, Broadens Partnership
2 months ago - By: Investor's Business Daily
- Mentions:
GSK
AZN
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
2 months ago - By: Sanofi
Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
Please enable JavaScript to continue using this application.